 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
FDA Clears Nanosphere's CYP2C19 Test to Guide Therapeutic Strategy, Not Predict Response
November 14, 2012
FDA Clears Nanosphere's CYP2C19 Test to Guide Therapeutic Strategy, Not Predict Response
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Researchers Studying Two Point-of-Care Tests to Gauge PGx Response to Anti-Platelet Drugs
August 11, 2010 / Pharmacogenomics Reporter - People in the News: Michael McGarrity, William Moffitt, Sheli Rosenberg, Michael Ward
February 20, 2013 / Pharmacogenomics Reporter - MDx/CDx Focus: Cepheid Updates BCR-ABL Test; Medicare Covers Transgenomic Plavix Dx; Lungevity Awards
July 25, 2012 / Pharmacogenomics Reporter - UF to Genotype All Comers at Cath Lab to Personalize Treatment with Plavix, Eventually Other Drugs
June 27, 2012 / Pharmacogenomics Reporter - Dx Developers' Sales Pitch to Pharma Could be Key Factor in Marketing Some Tests
February 15, 2012 / Pharmacogenomics Reporter